![Choline alfoscerate (Cerebroforce) injections 0.25 mg/ml 4 ml - [5 ampoules]](https://mediscom.com.co/wp-content/uploads/2022/11/Cerebroforce-250mg-4ml-5.webp)
Description
Cerebroforce Pharmacodynamics
Choline alfoscerate (Cerebroforce) is a cholinomimetic of central action with predominant influence on the central nervous system.
The drug contains 40.5% of choline, which is released from the compound in the brain; choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nerve excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.
Acetylcholine has a positive effect on nerve impulse transmission, and glycerophosphate participates in the synthesis of phosphatidylcholine (a membrane phospholipid), resulting in improved membrane elasticity and receptor function.
Choline alphoscerate enhances metabolic processes and activates structures of the reticular formation of the brain.
It has a preventive and corrective effect on factors of involutional psychoorganic syndrome, such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity.
Pharmacodynamic studies have shown that choline alphoscerate acts on synaptic, including cholinergic transmission of nerve impulse (neurotransmission), neuronal membrane plasticity and receptor function.
Indications
-Brain circulation disorders of ischemic type (acute and recovery period) and hemorrhagic type (recovery period).
-Psychoorganic syndrome against involutional and degenerative processes of the brain.
-Consequences of cerebrovascular insufficiency or primary and secondary cognitive disorders in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, decreased concentration of attention.
-Behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest; senile pseudo-melancholy.
-Multi-infarct dementia.
Contraindications .
-High sensitivity to the components of Choline alfoscerate (Cerebroforce).
-Pregnancy.
-Period of breast-feeding.
-Children under 18 years of age (due to lack of data).
Usage during pregnancy and lactation.
Usage of the drug choline alphoscertate is contraindicated during pregnancy and breastfeeding.
Dosage and administration method
- Intravenously (dropwise) or intramuscularly (slowly) at a dose of 1000 mg/day.
- During intravenous administration the contents of one ampoule (4 ml) are diluted in 50 ml of 0.9% sodium chloride solution, infusion rate is 60-80 drops per minute.
- The duration of treatment is usually 10 days. If necessary, treatment may be continued as prescribed by a physician depending on clinical picture and peculiarities of the disease course, age and drug tolerance.
- After stabilization of the patient’s condition it is possible to continue treatment with oral dosage forms of Choline alfoscerate (Cerebroforce).
Doses may be increased at the discretion of the attending physician.
